FDA Redraws the Line Between ANDAs and 505(b)(2)s

Before a generic drug developer writes a single protocol, it has to answer a threshold question: ANDA, or 505(b)(2)? Get it wrong and the application can be rejected outright, or saddled with studies the sponsor never planned for. On 18 August 2026, FDA published a draft guidance revising its seven-year-old answer to that question — the first update to "Determining Whether To Submit an ANDA or a 505(b)(2) Application" since May 2019.

Why this is the guidance every generics developer reads first

Sections 505(j) and 505(b)(2) of the Federal Food, Drug, and Cosmetic Act are both abbreviated routes to approval — both let a sponsor lean on FDA's prior finding that a reference product is safe and effective, instead of running a full independent development program. But they are not interchangeable. An ANDA under 505(j) is for a true duplicate: same active ingredient, strength, dosage form, route of administration and conditions of use as its reference listed drug, supported chiefly by bioequivalence data. A 505(b)(2) application covers products that differ from the reference product in ways an ANDA cannot accommodate — a new strength, a new dosage form, a new indication — and FDA can require the sponsor to generate additional data to support those differences, on a case-by-case basis it lays out in the guidance. FDA notes plainly that "many potential drug product developers are not familiar with the different abbreviated approval pathways for drug products" or with what data each one accepts, which is the gap this guidance exists to close.

What actually changed

FDA describes the substance of the 2026 revision narrowly: it adds detail on how the agency evaluates whether a proposed generic product qualifies as a "duplicate" of the reference listed drug, and is therefore eligible to proceed as an ANDA under 505(j), versus differing enough to require 505(b)(2). That eligibility determination is where borderline cases live — a formulation or delivery-device change that a sponsor believes is minor can be exactly the kind of difference that reroutes an application into the more demanding pathway. Sharper guidance on where FDA draws that line does not change the underlying statute, but it narrows the room for a sponsor to guess wrong and find out only after submission.

What to do before 19 October

• Re-check pathway calls already made for products in development against the revised duplicate-eligibility language, particularly for reformulations, new delivery devices or combination products sitting close to the ANDA/505(b)(2) line.
• File comments to Docket FDA-2017-D-5974 by 19 October 2026 if the revised eligibility criteria would reclassify a pipeline product's intended pathway.
• Watch for the final guidance, which will formally supersede the May 2019 version once issued; FDA has not stated a target date for finalization.